Upstream & Downstream Processing

Dover shells out $225m for bio-control instruments firm Malema

Biomanufacturing vendor Dover will bolster its Pumps & Process Solutions segment via the addition of Malema’s single-use flow sensor technology. The $225 million cash deal, expected to close in the second quarter, sees Dover add flow-measurement and control instruments maker Malema Engineering Corporation to its service offering. Malema, which is set to make approximately $40-45 million in sales in 2022, produces single-use flow sensors using Coriolis technology which it claims reduces the potential for measurement error and the need for calibration…

Cytiva opening Swiss single-use cell processing site

With work beginning weeks before the global pandemic, the plant has opened on schedule, boosting Cytiva’s capacity for single-use products aimed at supporting cell and gene therapy makers. The 7,400 m2 facility in Grens, Switzerland is set to have its official opening at the end of the month, strengthening bioprocess vendor Cytiva’s capabilities in providing single use kits for cell processing systems and their relevant consumables. The plant is ready 28 months after Cytiva – then known as GE Life…

Repligen: Robust bioprocess market will offset reduced COVID demand

Repligen has tweaked its guidance in the wake of diminishing COVID-related orders but remains positive going forward due to a “very strong order book” for its base business. For the first quarter 2022, Repligen Corporation reported record revenue of $206.4 million, 45% up on the same period last year. Despite this, the bioprocess vendor has reduced its full year guidance by 4% from $800-$830 million to $770-$800 million due to the fall in COVID-related demand, something expected to continue throughout…

Formulation lap: Sanofi turns to McLaren for manufacturing efficiency

Sanofi has teamed with Formula 1 racing team McLaren to optimise manufacturing efficiencies within its network. The multiyear deal will see Sanofi’s Industrial Affairs team benefit from McLaren Racing team’s digital and analytical expertise tto achieve excellence in manufacturing operations. “Analysis of losses, modelling and simulation of production line scheduling, and specifically product change-overs, will be key areas to maximise performance in Sanofi manufacturing sites,” McLaren said in a press release. Both Sanofi and McLaren Racing “operate in a truly…

Danaher and Sartorius: COVID just one variable affecting bioprocess growth

Comments from J&J have led to questions surrounding the long-term revenues from COVID-19 vaccines. However, the sector is just one area driving bioprocess growth, both Danaher and Sartorius say. While the COVID-19 virus is still virulent in some areas, the rapid development, scale-up, and delivery of vaccines over the past two years has helped bring the world back to some sense of normality. The unprecedented roll-out has resulted in hundreds-of-billions of dollars ending up in the pockets of several vaccine…

MAST away: Lonza sells bioreactor sampling tech to MilliporeSigma

MilliporeSigma says the addition of the MAST (Modular Automated Sampling Technology) platform will help its customers optimize their bioprocesses and speed up development time. Lonza is offloading the platform to bioprocess vendor and fellow contract manufacturer MilliporeSigma – the life sciences service division of Germany’s Merck – for an undisclosed fee. The technology provides biomanufacturers near real-time sampling and analysis of bioreactors, the results of which can be used to deliver a range of analytical devices measuring titer, metabolites, and…

Evonetix hits milestone in development of DNA synthesis

Synthetic biology company Evonetix has achieved enzymatic DNA synthesis capability with its thermally controlled synthesis chemistry, allowing the production of scarless DNA sequences. Evonetix is aiming to bring semiconductor technology to DNA synthesis and claims it has achieved enzymatic DNA synthesis through its thermally controlled synthesis chemistry, which is part of a three-year development program supported by Innovated UK and Durham University. The firm said the results demonstrate that its semiconductor array-based platform is compatible with enzymatic and chemical DNA…

The 4 degrees of automation in cell therapy manufacture

With cell therapy firms looking beyond manual production methods, Cellares claims its ‘factory-in-a-box’ Cell Shuttle platform can offer the ultimate in walk-away automation on an industrial-scale. For years, industry has looked to automated processes to make cell therapies safely and at scale. Success has been variable, but developers continue investing in automated technologies to help make their complex therapies cost-effective. “A lot of people agree that automation is the way to go,” Fabian Gerlinghaus, co-founder and CEO of Cellares told…

Maravai LifeSciences: $11bn+ would deliver Sartorius a nucleic acid unit

According to media reports, Sartorius is looking to buy Maravai LifeSciences. We look at how such an acquisition may bolster Sartorius’ biopharma arsenal through a robust nucleic acid business. A Reuters exclusive last week claimed Sartorius made an offer to buy fellow life science vendor Maravai for $42 per share, or roughly $11 billion. The offer was allegedly rebuffed, according to sources close to the matter. Maravai provides products and services to enable the development and manufacture of drug therapies,…

eBook: Gene Therapies —
Developers Slowly Emerge from a Pandemic

This eBook gauges shifting expectations for the gene therapy industry amid the COVID-related uncertainties and clinical setbacks of the past couple years. BioProcess Insider founding editor Dan Stanton reports on the January 2022 Phacilitate Advanced Therapies Week event, specifically a standing presentation on the 10 most important industry drivers from the past year. Since 2017, advancements in gene therapies have featured prominently in these presentations. In 2021, gene therapies again made the list, but this time for more troubling reasons,…